Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Monday, March 7, 2022
According to research presented in PLOS One, patients with multiple myeloma who undergo high-dose melphalan treatment in the context of hematopoietic stem cell transplantation may experience fewer transplant-related toxicities if they receive the nutritional supplements resveratrol and copper. Indraneel Mittra, MD, PhD, of the Homi Bhabha National Institute in Mumbai, and colleagues posited that oral administration of these nutraceuticals may contribute to the inactivation of cell-free chromatin particles, common propagators of chemotherapy toxicity.
Between March 2017 and August 2019, the RESCU 001 study enrolled 25 patients, 5 of whom received the treatment vehicle alone (control), 5 of whom received 5.6 mg of resveratrol and 0.56 μg of copper (dose level I), and 5 of whom received 50 mg of resveratrol and 5 μg of copper (dose level II). Doses were administered 48 hours prior to the receipt of melphalan and continued twice daily until at least 21 days following transplantation.
Grade 3 or 4 oral mucositis occurred in 100% of the control group versus 40% of both dose-level groups combined (P = .039). Measurements of tumor necrosis factor in terms of alpha and interleukin-1 beta, both taken from patient saliva, indicated that a reduction in inflammatory cytokines occurred in the dose-level I group but not in the dose-level II group.
“We conclude that relatively inexpensive nutraceuticals may be useful as adjuncts to chemotherapy to reduce its toxicity,” noted the authors.
Disclosure: For full disclosures of the study authors, visit journals.plos.org.
JNCCN Spotlights
